Clinical Trial

MB-105 in Patients With CD5 Positive T-cell Lymphoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-07-31; most recent amendment 2025-09-30.
Status change: Not Yet Recruiting → Recruiting 2025-01-23
Trial Details
NCT Number NCT06534060
Lead Sponsor March Biosciences Inc
Conditions Lymphoma, T-Cell
Enrollment 46 participants
Start Date 2025-02-15
Primary Completion 2028-02 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2025-10-03